Who Paid My Doc
Cara Fanning
Infectious Disease Las Vegas, NV Medical Doctor
NPI 1841288107 CMS profile 310926
3483 S Eastern Ave, Las Vegas, NV 89169
General payments
$2,202
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Cara Fanning of Las Vegas, NV is reported in the CMS Open Payments database as having received $2,202 across 102 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 73rd percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $271 | 11 | |
| 2024 | General | $326 | 13 | |
| 2023 | General | $303 | 12 | |
| 2022 | General | $360 | 13 | |
| 2021 | General | $264 | 14 | |
| 2020 | General | $152 | 10 | |
| 2019 | General | $526 | 29 |
Beside peers
- Cara Fanning
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Cara Fanning were reported at $271. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Cara Fanning | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $526 | $190 | $60–$862 | $163 |
| 2020 | $152 | $124 | $32–$606 | $114 |
| 2021 | $264 | $148 | $38–$905 | $132 |
| 2022 | $360 | $166 | $50–$834 | $149 |
| 2023 | $303 | $171 | $57–$787 | $160 |
| 2024 | $326 | $176 | $52–$752 | $164 |
| 2025 | $271 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 16 drugsPart D claims
657
Drug cost
$491,821
Branded share of claims
39.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Daptomycin | Generic | 177 | $271,871 | |
| Dovato Dolutegravir Sodium/Lamivudine | Brand | 18 | $60,692 | |
| Meropenem | Generic | 101 | $45,134 | |
| Ertapenem Ertapenem Sodium | Brand | 86 | $43,086 | |
| Teflaro Ceftaroline Fosamil Acetate | Brand | 11 | $18,265 | |
| Imipenem-Cilastatin Sodium Imipenem/Cilastatin Sodium | Brand | 38 | $16,647 | |
| Piperacillin-Tazobactam Piperacillin Sodium/Tazobactam | Brand | 43 | $9,132 | |
| Cefepime Hcl | Generic | 31 | $8,529 | |
| Linezolid-D5w Linezolid In Dextrose 5% | Brand | 11 | $7,359 | |
| Micafungin Micafungin Sodium | Brand | 22 | $5,734 |
The 10 drugs with the highest cost, of 16 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 6 billing codesPaid by Medicare
$71,918
Medicare patients
71
Services billed
931
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 69% | |
| Arthritis | 69% | |
| Chronic kidney disease | 56% | |
| Ischemic heart disease | 52% | |
| Heart failure | 46% | |
| Depression | 46% | |
| COPD | 42% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 9 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| REBYOTA |
|
$86 | — | — |
| ZERBAXA |
|
$65 | — | — |
| DIFICID |
|
$57 | — | — |
| DOVATO |
|
$26 | 18 | — |
| PIFELTRO |
|
$18 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 9 in the dashboard with a free accountRecords
102 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in Nevada
Related records
Infectious Disease in Nevada
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Nevada
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.